TY  - JOUR
T1  - RAndomized, double-blind, placebo-controlled trial of 2 dosages of sustained-release bupropion for adolescent smoking cessation
AU  - Muramoto ML, Leischow SJ, Sherrill D, Matthews E, Strayer LJ
Y1  - 2007/11/01
N1  - 10.1001/archpedi.161.11.1068
JO  - Archives of Pediatrics & Adolescent Medicine
SP  - 1068
EP  - 1074
VL  - 161
IS  - 11
N2  - Objective 
    To assess the safety and efficacy of sustained-release bupropion hydrochloride for adolescent smoking cessation.Design 
    Prospective, randomized, double-blind, placebo-controlled, dose-ranging trial.Setting 
    Metropolitan areas of Tucson and Phoenix, Arizona.Participants 
    Adolescents (N = 312) recruited through media and various community venues from March 1, 1999, through December 31, 2002, who were aged 14 to 17 years, smoked 6 or more cigarettes per day, had an exhaled carbon monoxide level of 10 ppm or greater, had at least 2 previous quit attempts, and had no other current major psychiatric diagnosis.Intervention 
    Sustained-release bupropion hydrochloride, 150 mg/d (n = 105) or 300 mg/d (n = 104), or placebo (n = 103) for 6 weeks, plus weekly brief individual counseling. Subjects were followed up at 12 weeks (by telephone call) and 26 weeks.Main Outcome Measure 
    Confirmed 7-day point prevalence abstinence at 6 weeks and 30-day prolonged abstinence (carbon monoxide level < 10 ppm at each visit; urinary cotinine level ≤ 50 μg/L at weeks 2 and 6).Results 
    Cotinine-confirmed 7-day point prevalence abstinence rates at 6 weeks were as follows: placebo, 5.6%; 150 mg, 10.7%; and 300 mg, 14.5% (P = .03, 300 mg vs placebo). At 26 weeks, confirmed point prevalence abstinence rates were as follows: placebo, 10.3%; 150 mg, 3.1%; and 300 mg, 13.9% (P = .049). During treatment, confirmed point prevalence rates were significantly higher for 300 mg than placebo at every week except week 4.Conclusions 
    Sustained-release bupropion hydrochloride, 300 mg/d, plus brief counseling demonstrated short-term efficacy for adolescent smoking cessation. Abstinence rates were lower than those reported for adults, with rapid relapse after medication discontinuation.Trial Registration 
    clinicaltrials.gov Identifier: NCT00344695
SN  - 1072-4710
M3  - doi: 10.1001/archpedi.161.11.1068
UR  - http://dx.doi.org/10.1001/archpedi.161.11.1068
ER  -